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NTBC and Alkaptonuria
To the Editor:
La Du (1998) sounds an appropriate note of caution in
posing the editorial question, “Are we ready to try to
cure alkaptonuria?” (i.e., with homogentisate 1,2-diox-
ygenase [HGO] gene-replacement therapy). He suggests
that localization of recombinant HGO to certain tissues
might lead to accumulation of reactive intermediates of
the tyrosine catabolic pathway. We would like to point
out an alternative therapy for alkaptonuria (La Du 1995;
MIM 203500) that obviates the problem of gene
localization.
The potential treatment consists of oral administra-
tion of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclo-
hexanedione, or NTBC, in combination with some di-
etary restriction of phenylalanine and tyrosine. NTBC
is a member of the triketone class of herbicides, which
cause plants to bleach. The triketone herbicides are
inhibitors of 4-hydroxyphenylpyruvate dioxygenase
(HPPD) (Schulz et al. 1993), the enzyme that produces
homogentisic acid (HA). Hence, NTBC should prevent
the production of HA, which is believed to cause the
signs and symptoms of alkaptonuria. NTBC binds to 4-
HPPD in a rapid and avid (inhibitory concentration
[IC]50  40 nM), but reversible, fashion and inhibits
both rat and human liver HPPD (Lindstedt et al. 1992;
Schulz et al. 1993).
NTBC is the first effective drug therapy for the fatal
hereditary disease tyrosinemia type I (Mitchell et al.
1997), which results from fumarylacetoacetate hydro-
lase deficiency. By reducing the supply of HA, NTBC
partially blocks the formation of fumarylacetoacetate
and thus lowers the concentration of oxidizing metab-
olites, which cause severe liver disease, hepatocellular
carcinoma, and renal tubular dysfunction in infants and
children with tyrosinemia type I (Mitchell et al. 1997).
Early studies have shown both biochemical and clinical
efficacy of NTBC (Lindstedt et al. 1992), and case re-
ports indicate improvement in peripheral neuropathy
(Gibbs et al. 1993) and renal disease (Pronicka et al.
1996). A murine model of tyrosinemia type I was treated
with NTBC and responded with increased longevity, im-
proved liver function, and partially normalized expres-
sion of hepatic mRNAs (Grompe et al. 1995). The only
side effect was liver steatosis.
In humans, NTBC appears to be well tolerated for
short and midterm administration and has been used at
least since 1992 (Lindstedt et al. 1992). Complica-
tions—namely, photophobia and the presence of corneal
crystals—have been observed in only one NTBC-treated
child. These findings disappeared within 48 h, when a
phenylalanine and tyrosine-restricted diet was intro-
duced, and did not recur subsequently (Mitchell et al.
1997). Theoretically, NTBC therapy could result in neu-
rological problems associated with tyrosinemia type II
(tyrosine aminotransferase deficiency) or with tyrosi-
nemia type III (4-HPPD deficiency) (Mitchell et al.
1997). Tyrosinemia type III has been diagnosed in only
two patients, both of whom were ascertained because
of neurological problems. One patient had mild ataxia,
and the other had seizures and cerebral atrophy. Since
these patients were evaluated because of their neurolog-
ical symptoms, a causal relationship between their bi-
ochemical abnormalities and neurological symptoms
cannot be determined. Patients treated with NTBC have
not been reported to experience neurological problems,
but dietary restriction of tyrosine and phenylalanine may
be important for the prevention of any neurological,
ophthalmological, and dermatological side effects of
high tyrosine levels.
Because NTBC side effects have been reported for only
a few patients, it may be prudent to await a more-de-
tailed analysis of the entire group of tyrosinemia type I
patients who have been treated with NTBC. However,
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in anticipation that the side effects will prove to be min-
imal, we propose to evaluate the safety and efficacy of
NTBC for alkaptonuria patients. With the cooperation
of Dr. C. Ronald Scott of the University of Washington,
we now are attempting to secure NTBC for use in the
treatment of alkaptonuria.
Whereas gene therapy generally involves specific tissue
localization, pharmacotherapy routinely employs a wide
range of targets. For many metabolic disorders, this pro-
vides a distinct advantage. For example, in the treatment
of cystinosis, cysteamine has beneficial effects upon a
variety of organs and tissues (Gahl et al. 1995), including
the kidney, muscle, cornea, and thyroid (Kimonis et al.
1995). NTBC could have multisystemic salutary effects
as well, meaning that we really are ready to try to cure
alkaptonuria.
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Gene Localization for Aculeiform Cataract, on
Chromosome 2q33-35
To the Editor:
Aculeiform cataract (MIM 115700) is a form of con-
genital crystalline cataract that originally was described
by Vogt in 1922 and was referred to as “Spiesskatarakt”
(Vogt 1922). Since its original description, this entity
also has been referred to as “frosted cataract,” “needle-
shaped cataract,” or “fasciculiform cataract” (Parker
1956). This phenotype is characterized by fiberglasslike
or needlelike crystals projecting in different directions,
through or close to the axial region of the lens (fig. 1).
Some crystals may be 11 mm in length, and their bio-
chemical composition is not known. This type of cata-
ract is considered to be different from the corraliform
cataract, which does not show the needlelike projections.
This opacity does not appear to respect the sutures or
the direction of the lens fibers (Franc¸ois 1963) and ap-
pears to originate from the fetal and postnatal nuclei,
suggesting a congenital origin with some postnatal pro-
gression, if any. The opacity causes a variable degree of
